| PFND Stock | | | USD 0.0001 0.00 0.00% |
Chairman
Mr. Joerg Gruber is a Chairman of the Board of Pathfinder Cell Therapy, Inc., since September 2011 and as a director since April 2007. Mr. Gruber cofounded Clubb Capital Limited, a Londonbased corporate finance and VC firm with a principal focus on healthcare, in 1995 and was its Chairman since 1999. Prior to his career in VC, Mr. Gruber spent 14 years in banking and investment banking at UBS, Goldman Sachs and Lehman Brothers. Mr. Gruber cofounded Pathfinder, LLC with Dr. Franklin. Mr. Gruber has served as Chairman of Pathfinder, LLC since 2008 and as Chairman of Tarix Pharmaceuticals since 2007. Mr. Gruber is Chairman of Tarix Orphan LLC, a company focused on the development of peptides to treat muscular dystrophy and Marfan syndrome and is also a director of AvidBiologics Inc., a privatelyheld biopharmaceutical company specializing in the development of oncology products. since 2011.
| Age | 62 |
| Tenure | 13 years |
| Phone | 617-245-0289 |
| Web | https://www.pathfindercelltherapy.com |
Pathfinder Cell Management Efficiency
The company has return on total asset
(ROA) of
(8.8876) % which means that it has lost $8.8876 on every $100 spent on assets. This is way below average. Pathfinder Cell's management efficiency ratios could be used to measure how well Pathfinder Cell manages its routine affairs as well as how well it operates its assets and liabilities.
Pathfinder Cell Therapy currently holds 5.41
M in liabilities. Debt can assist Pathfinder Cell until it has trouble settling it off, either with new capital or with free cash flow. So, Pathfinder Cell's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Pathfinder Cell Therapy sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Pathfinder to invest in growth at high rates of return. When we think about Pathfinder Cell's use of debt, we should always consider it together with cash and equity.
Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts. PATHFINDER CELL operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs 1 people. Pathfinder Cell Therapy [PFND] is a
Pink Sheet which is traded between brokers as part of OTC trading.
Management Performance
Pathfinder Cell Therapy Management Team
Elected by the shareholders, the Pathfinder Cell's board of directors comprises two types of representatives: Pathfinder Cell inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pathfinder. The board's role is to monitor Pathfinder Cell's management team and ensure that shareholders' interests are well served. Pathfinder Cell's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pathfinder Cell's outside directors are responsible for providing unbiased perspectives on the board's policies.
Pathfinder Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Pathfinder Cell a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
Other Information on Investing in Pathfinder Pink Sheet
Pathfinder Cell financial ratios help investors to determine whether Pathfinder Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pathfinder with respect to the benefits of owning Pathfinder Cell security.